Disclosures: Richard Morrow: Nothing to Disclose, Dahn Jeong: Nothing to Disclose, Jean Makuza: Nothing to Disclose, Michael Irvine: Nothing to Disclose, Alnoor Ramji: Nothing to Disclose, Hin Hin Ko: Nothing to Disclose, Mel Krajden: Nothing to Disclose, Sofia Bartlett: Nothing to Disclose, Stanley Wong: Nothing to Disclose, Amanda Yu: Nothing to Disclose, JASON WONG: Nothing to Disclose, Julia Li: Nothing to Disclose, Naveed Janjua: Nothing to Disclose 381 HEPATITIS B TREATMENT OUTCOMES AND FACTORS ASSOCIATED WITH HBV TREATMENT SUCCESS: A POPULATION-BASED STUDY IN RWANDA Jean Damascene Makuza 1 Dahn Jeong 2 Atul Aravindakshan 3 Richard Morrow 3 Prince Adu 4 Marie Paul Nisingizwe 3 Georgine Cua 4 Hctor Velsquez Garca 4 Janvier Serumondo 5 Albert Tuyishime 5 Joseph Puyat 3 Joseph Puyat 3 Alnoor Ramji 2 Michael Law 3 Naveed Janjua 4 , 1 The University of British Columbia, SPPH, 2 University of British Columbia, 3 The University of British Columbia, 4 British Columbia Centre for Disease Control, 5 Rwanda Biomedical Centre Background: Timely treatment of chronic hepatitis B virus (HBV) infection reduces complications such as cirrhosis and hepatocellular carcinoma and improves overall survival

How Microdosing Tirzepatide Became a Trend Microdosing tirzepatide has become an emerging area of interest, discussed on social media and within wellness circles
Out of pocket costs for patients also vary, since formulary tier placement and cost-sharing for prescription drugs are not uniform
Ozempic can be expensive, but Costco often offers competitive pricing, especially with insurance, discounts, or coupons
Employers are largely accepting the use of GLP-1s for diabetes and weight loss
Consider checking a full micronutrient panel after a year on therapy, or sooner if symptoms arise